Outlook Therapeutics (OTLK) Earnings Analysis

Outlook Therapeutics (OTLK) next reports earnings on 2026-08-13, consensus EPS -0.09 USD. Last quarter (2026-05-15) it missed with EPS -0.16 USD vs -0.12 USD est (-33.3%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E -0.98.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does OTLK next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.09 USD
Revenue estimate0.00B

OTLK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.16 USD-0.12 USD-33.3%Miss
2026-02-17-0.22 USD-0.17 USD-29.4%Miss
2025-12-19-0.22 USD-0.26 USD+15.4%Beat
2025-08-14-0.44 USD-0.42 USD-4.8%Miss
2025-05-15-0.4 USD-0.55 USD+27.3%Beat
2025-02-14-0.89 USD-0.85 USD-4.7%Miss
2024-12-27-0.77 USD-0.83 USD+7.2%Beat
2024-08-14-0.83 USD-1.06 USD+21.7%Beat

Beat rate: 4/8 (50%) over reported quarters with consensus data.

OTLK valuation and analyst view

Trailing P/E-0.98
Trailing EPS-0.74486 USD
Price / book-3.78
Dividend yield0.00%
Market cap0.05B
Analyst consensusBuy (7 buy / 7 hold / 0 sell)
Avg price target1 USD

Related research pages

Frequently asked questions

When is Outlook Therapeutics (OTLK)'s next earnings date?

Outlook Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.09 USD and revenue estimate of 0.00B.

Did OTLK beat earnings last quarter?

In its 2026-05-15 report, OTLK posted EPS of -0.16 USD versus a -0.12 USD estimate — a miss of 33.3%.

What is OTLK's earnings track record?

Over the last 8 reported quarters with consensus data, OTLK beat estimates 4 times (50%).

What is OTLK's current P/E ratio and EPS?

OTLK trades at a trailing P/E of -0.98 on trailing EPS of -0.7448615157143555 USD.

What do analysts rate OTLK?

Analyst consensus is "Buy" across 14 ratings (0 strong buy, 7 buy, 7 hold, 0 sell, 0 strong sell). Average 12-month price target: 1 USD.